GovChime
IDVOther than small business

IDC (multiple-award IDV) HHSN261201700014ISRI INTERNATIONAL

Overview

Award facts

Obligated on orders under this IDV
$232.12K
$232,120 across 9 orders
Period of performance
From Aug 1, 2017
Modifications
1
Latest action Nov 4, 2021
Contract type
IDC (multiple-award IDV)
PIID HHSN261201700014I

Description of requirement

IGF::OT::IGF ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS

Dates and value

Award date
Signed on Aug 1, 2017
Ordering period ends
Jul 31, 2022
Ceiling
Shared program ceiling (all awardees of this multiple-award vehicle, not a per-awardee value): $5,000,000

Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Nov 4, 2021. View on USAspending · Recipient on SAM.gov

Recipient

LocationMENLO PARK, CA
UEISRG2J1WS9X63
CAGE code03652
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeCorporate tax exempt
Parent companySRI INTERNATIONAL

Business types and certifications

Nonprofit organizationTax-exempt corporation

As represented in SAM.gov at the time of the action.

Subcontracting network

The prime, the subcontractors on this award, and their own subcontractors.

Subaward amounts are self-reported by prime contractors to SAM.gov and appear 1 to 2 months after the work. Duplicates are removed on a best-effort basis. Totals are incomplete and not an audit. Source: USAspending.

Agency and place

Awarding and funding

Funded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NIH NCI

Classification and competition

Classification

Competition

Extent competed
Full and open competitionA
Solicitation procedures
Negotiated proposal/quoteNP
Set-aside
No set-aside used
Contract pricing
Order dependent (IDV allows pricing arrangement to be determined separately for each order)1
Offers received
4

Solicitation and notices

Solicitation ID
N02CM7700416(as reported)

Contract details

Subcontracting plan
Individual subcontract planF
Major program
Analysis of anti-cancer chemicals and pharmaceutical formulations
Cost Accounting Standards clause
Yes - CAS clause includedY
Certified cost or pricing data
Yes
Commercial procedures
Commercial item procedures not usedD
Government-furnished property
Transaction does not use GFE/GFPN
Bundled requirement
Not bundledH
Consolidated requirement
Not consolidatedD
Undefinitized action (terms not final)
No
Multi-year contract
No
Performance-based service acquisition
No - service where PBA is not used.N

Linked notices

Notice
Notice ID
Type
Link
Posted

Transaction history

Modification history

Base award
Aug 1, 2017
Latest action
Nov 4, 2021 — Other administrative actionModification P00001; administrative: no change in scope or value
Actions by type
  • Base award1
  • Other administrative action1
2 actions recorded, Aug 1, 2017 to Nov 4, 2021; each action counted once.

Similar awards

PIID
Match
Awardee

All contract data

All contract data

Every other field reported for this award, as of its latest reported action

Competition

Evaluation preference
No preference used
Local area set-aside
No
Synopsized publicly (SAM.gov / FedBizOpps)
Yes
Simplified procedures for commercial items
No
A-76 (FAIR Act) action
No

Socio-economic and policy

Inherently governmental functions
Other functionsOT
Recovered materials and sustainability
FAR 52.223-4 and FAR 52.223-9 includedB
Clinger-Cohen Act planning (IT)
No

Place and origin

Domestic or foreign entity
U.S. owned businessA

Structure

Award or IDV
IDV
IDV type
IDCB
Indefinite-delivery contract type
Indefinite delivery / indefinite quantityB
Multiple or single award
Multiple awardM
Awarding agency code
7500
Awarding sub-tier code
7529
Contracting office code
75N910
Transactions recorded under this award key
2

Funding

Funding agency code
7500
Funding sub-tier code
7529
Funding office code
75N910